Skip to main content
SpringerLink
Log in
Book cover

Lung Cancer pp 293–321Cite as

Interferon and lung cancer

  • Chapter

  • 128 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 72))

Abstract

Interferons are glycoproteins produced by many of the body’s cells in response to foreign proteins such as viruses, microbes or tumors. There are three types of interferon (IFN): alpha (IFNα), produced by leukocytes; beta (IFNβ), produced by fibroblasts, macrophages and epithelial cells; and gamma (IFNγ), produced by activated T-lymphocytes and natural killer lymphocytes. There are at least 17 genes controlling the production of IFNα, but only one gene for IFNβ and one for IFNγ [1].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesei DW, Kumpel GR, Stanton GJ, Hughes TK. 1991. The interferons — mechanisms of action and clinical applications. JAMA 266:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  2. Rosenberg SA, Lotze MT, Yand JC, et al. 1989. Combination therapy with interleukin 2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874.

    PubMed  CAS  Google Scholar 

  3. Redman BG, Flaherty L, Chou TH, et al. 1990. A phase I trial of recombinant interleukin 2 combined with recombinant interferon gamma in patients with cancer. J Clin Oncol 8:1269–1276.

    PubMed  CAS  Google Scholar 

  4. Pestka S, Langer JA, Zoon KC, Samuel CE. 1987. Interferons and their actions. Ann Rev Biochem 56:727–777.

    Article  PubMed  CAS  Google Scholar 

  5. Wells V, Mallucci L. 1985. Expression of the 2–5 A system during the cell cycle. Exp Cell Res 159:27–36.

    Article  PubMed  CAS  Google Scholar 

  6. Contente S, Kenyon K, Rimoldi D, Friedman RM. 1990. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 249:796–798.

    Article  PubMed  CAS  Google Scholar 

  7. Langdon SP, Rabiasz GJ, Anderson L, Ritchie AA, Fergusson RJ, Hay FG, Miller EP, Mullen P, Plumb J, Miller WR, Smyth JF. 1991. Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon. Br J Cancer 63:909–915.

    Article  PubMed  CAS  Google Scholar 

  8. Tamm L, Jasny BR, Pfeffer LM. 1987. Antiproliferative action of interferons. In Mechanisms of Interferon Action, Vol. 2, M Pfeffer (ed.). CRC Press: Boca Raton, FL, pp. 25–58.

    Google Scholar 

  9. Bepler G, Carney DN, Nau MM, Gazdar AF, Minna JD. 1986. Additive and differential biological activity of α-interferon A, difluoromethylornithine and their combination on established human lung cancer cell lines. Cancer Res 46:3413–3419.

    PubMed  CAS  Google Scholar 

  10. Sekar V, Atmar VJ, Joshi AR, Krim M, Kuehn G. 1983. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 114:950–954.

    Article  PubMed  CAS  Google Scholar 

  11. Yasui H, Takai K, Yoshida R, Hayaishi O. 1986. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 83:6622–6626.

    Article  PubMed  CAS  Google Scholar 

  12. Fleischmann WR Jr, Newton RC, Fleischmann CM, Colburn NH, Brysk MM. 1984. Discrimination between nonmalignant and malignant cells by combination of IFNγ and IFNa/β. J Biol Response Mod 3:397–405.

    PubMed  CAS  Google Scholar 

  13. Billiau A. 1983. The pharmacokinetics and toxicology of interferon. In Interferons: From Molecular Biology to Clinical Application, DC Burke and AG Morris (eds.). Cambridge University Press: Cambridge, pp. 255–276.

    Google Scholar 

  14. Marley GM, Doyle LA, Ordóñez JV, Sisk A, Hussain A, Chiu Yen R-W. 1989. Potentiation of interferon induction of class I histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines. Cancer Res 49:6232–6236.

    PubMed  CAS  Google Scholar 

  15. Schwartz BD. 1991. HLA molecules: sentinels of the immune response. Am J Respir Cell Mol Biol 5:211–212.

    PubMed  CAS  Google Scholar 

  16. Funa K, Gazdar AF, Mattson K, Niiranen A, Koivuniemi A, Öberg K, Wilander E, Doyle A, Linnoila RI. 1986. Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clin Immunol Immunopathol 41:159–164.

    Article  PubMed  CAS  Google Scholar 

  17. Crawford J, Ringenberg S, Propert K, Glenn L, Modeas C, Christenson V, Jaffe H, Green M. 1989. A dose response study of the biological activity of interferon-gamma (IFN-G) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 8:A867.

    Google Scholar 

  18. Jabbar SAB, Twentyman PR. Relationship between growth inhibition by cytokines (interferon and tumour necrosis factor) and receptor binding in human lung cancer cell lines.

    Google Scholar 

  19. Suarez-Pestano ER, Bjorklund GC, Bergh J, Larsson R, Nilsson K, Pereda CM. 1991. Development of a new interferon alpha-resistant cell line from small-cell lung carcinoma cell line H-82. J Tumor Marker Oncol 6(4):73.

    Google Scholar 

  20. Thomassen MJ, Wiedemann HP, Barna BP, Farmer M, Ahmad M. 1988. Induction of in vitro tumoricidal activity in alveolar macrophages and monocytes from patients with lung cancer. Cancer Res 48(14):3949–3953.

    PubMed  CAS  Google Scholar 

  21. Murray HW, Scavuzzo D, Jacobs JL, Kaplan MH, Libby DM, Schindler J, Roberts RB. 1987. In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. J Immunol 138:2457–2462.

    PubMed  CAS  Google Scholar 

  22. Sechler JMG, Malech HL, White CJ, Gallin JI. 1988. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci 85:4874–4878.

    Article  PubMed  CAS  Google Scholar 

  23. Jaffe HA, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, Jaffe HS, Kramer S, Sherwin S, Crystal RG. 1991. Organ specific cytokine therapy. J Clin Invest 88:297–302.

    Article  PubMed  CAS  Google Scholar 

  24. Badger AM, Meunier PC, Weiss RA, Bugelski PJ. 1988. Modulation of rat broncho-alveolar lavage cell function by the intratracheal delivery of interferon-gamma. J Interferon Res 8:251–260.

    Article  PubMed  CAS  Google Scholar 

  25. Debs RJ, Fuchs HJ, Philip R, Montgomery AB, Brunette EN, Liggitt D, Patton JS, Shellito JE. 1988. Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats. J Immunol 140:3482–3488.

    PubMed  CAS  Google Scholar 

  26. Kawatsu H, Hasegawa Y, Takagi E, Shimokata K. 1991. Human alveolar macrophages of anergic patients with lung cancer lack the responsiveness to recombinant interferon gamma. Chest 100:1277–1280.

    Article  PubMed  CAS  Google Scholar 

  27. Tsuruo T, Lida H, Tsukagoshi S, Olu T, Kishida T. 1982. Different susceptibilities of cultured mouse cell lines to mouse interferon. Gann 73:42–47.

    PubMed  CAS  Google Scholar 

  28. Twentyman PR, Workman P, Wright KA, Bleehen NM. 1985. The effects of α and γ interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer 52:21–29.

    Article  PubMed  CAS  Google Scholar 

  29. Carney DN. 1991. Lung cancer biology. Eur J Cancer 27:366–369.

    Article  PubMed  CAS  Google Scholar 

  30. Lagadec PF, Saraya KA, Balkwill FR. 1991. Human small cell lung cancer cells are cytokine-resistant but NK/LAK sensitive. Int J Cancer 48(2):311–317.

    Article  PubMed  CAS  Google Scholar 

  31. Grönberg A, Ferm M, Tsai L, Kiessling R. 1989. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells. Cell Immunol 118:10–21.

    Article  PubMed  Google Scholar 

  32. Gazdar AF, Kadoyama C, Venzon D, Park J-G, Tsai C-M, Linnoila RI, Mulshine JL, Ihde DC, Giaccone G. 1992. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 13:191–196.

    PubMed  Google Scholar 

  33. Munker M, Munker R, Saxton RE, Koeffler HP. 1987. Effect of recombinant monokines, lymphokines and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 47:4081–4085.

    PubMed  CAS  Google Scholar 

  34. Jabbar SAB, Twentyman PR. 1990. The use of clonogenic assays in assessing the response of human lung cancer cell lines to alpha-and gamma-interferons alone or in combination with adriamycin. Int J Cancer 46:546–551.

    Article  PubMed  CAS  Google Scholar 

  35. Schiller JH, Groveman DS, Schmid SM, Willson JKV, Cummings KB, Borden EC. 1986. Synergistic antiproliferative effects of human recombinant α54-or βser-interferon with γ-interferon on human cell lines of various histogenesis. Cancer Res 46:483–488.

    PubMed  CAS  Google Scholar 

  36. Wadler S, Schwartz EL. 1990. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473–3486.

    PubMed  CAS  Google Scholar 

  37. Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR, Smyth JF. 1986. Augmentation of cytotoxicity of chemotherapy by human α-interferons in human non-small cell lung cancer xenografts. Cancer Res 46:4916–4920.

    PubMed  CAS  Google Scholar 

  38. Cole SP, Campigotto BM, Johnson JG, Elliot BE. 1991. Differential growth inhibition and enhancement of major histocompatiability complex Class I antigen expression by interferons in a small cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. Cancer Immunol Immunother 33:274–277.

    Article  PubMed  CAS  Google Scholar 

  39. Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, Saito S, Masuno T, Kodama N, Furuse K, et al. 1992. High sensitivity to peripheral blood lymphocytes and low HLA Class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity. Jpn J Cancer Res 83(7):736–745.

    Article  PubMed  CAS  Google Scholar 

  40. Kardamakis D, Gillies NE, Soulhami RL, Bewerley PCL. 1989. Recombinant human interferon alpha-2b enhances the radiosensitivity of small cell lung cancer in vitro. Anticancer Res 9:1041–1044.

    PubMed  CAS  Google Scholar 

  41. Dritschilo A, Mossman K, Gray M, Sreevalan T. 1982. Potentiation of radiation injury by interferon. Am J Clin Oncol 5:79–82.

    PubMed  CAS  Google Scholar 

  42. Carney DN, Mitchell JB, Kinsella TT. 1983. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43:2806–2811.

    PubMed  CAS  Google Scholar 

  43. Chang AYC, Keng PC. 1987. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 47:4338–4341.

    PubMed  CAS  Google Scholar 

  44. Lvovsky EA, Mossman KL, Levy HB, Dritschilo A. 1985. Response of mouse tumour to interferon inducer and radiation. Int J Radiat Oncol Biol Phys 11:1721–1726.

    Article  PubMed  CAS  Google Scholar 

  45. Tsai C-M, Ihde DC, Kadoyama C, Venzon D, Gazdar AF. 1990. Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Eur J Cancer 26(11/12):1148–1152.

    PubMed  CAS  Google Scholar 

  46. Salmon SE. 1990. Chemosensitivity testing: another chapter. J Natl Cancer Inst 82(2): 82–83.

    Article  PubMed  CAS  Google Scholar 

  47. Färkkilä M, Niiranen A, Mattson K, Salmi T, Iivanainen M, Cantell K. 1986. Neuro-toxicity of high-or low-dose natural IFN-α and of recombinant IFN-γ in patients with lung cancer. In The Biology of the Interferon System. Elsevier: Amsterdam.

    Google Scholar 

  48. Mattson K, Niiranen A, Pyrhönen S, Färkkilä M, Cantell K. 1991. Recombinant interferon gamma treatment in non-small cell lung cancer. Acta Oncol 30(5):607–610.

    Article  PubMed  CAS  Google Scholar 

  49. Known S, Stoopler M, Cunningham-Rundles S, Oettgen HF. 1980. Phase II trial of human leukocyte interferon in non-small cell lung cancer. Proc Am Assoc Cancer Res 21:179.

    Google Scholar 

  50. Stoopler MB, Krown SE, Gralla RJ, Cunningham-Rundles S, Stewart WE, Oettgen HF. 1980. Phase II trial of human leukocyte interferon in non-small cell lung cancer. In II World Conference on Lung Cancer, Abstracts. Copenhagen, p. 221.

    Google Scholar 

  51. Figlin RA, Sarna GP, Callaghan M. 1983. Alpha (human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. J Biol Respir Modif 2:343–347.

    Google Scholar 

  52. Leavitt RD, Duffey P, Aisner J. 1984. A phase II study of recombinant leukocyte-A interferon in non-small cell carcinoma of the lung. Proc ASCO 3:52.

    Google Scholar 

  53. Grunberg SM, Kempf RA, Itri LM, Venturi CL, Boswell WD, Mitchell MS. 1985. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 69:1031–1032.

    PubMed  CAS  Google Scholar 

  54. Olesen BK, Ernst P, Nissen MH, Hansen HH. 1987. Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung: a Phase II study. Eur J Cancer Clin Oncol 23(7):987–989.

    Article  PubMed  CAS  Google Scholar 

  55. Niiranen A, Holsti LR, Cantell K, Mattson K. 1990. Natural interferon-alpha alone and in combination with conventional therapies in non-small cell lung cancer. Acta Oncol 29: 927–930.

    Article  PubMed  CAS  Google Scholar 

  56. van Zandwijk N, Jassem E, Dubbelman R, Braat MCP, Rumke P. 1990. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer 26:738–740.

    Article  PubMed  Google Scholar 

  57. Kinnula V, Cantell K, Mattson K. 1990. Effect of inhaled natural interferon-alpha on diffuse bronchioloalveolar carcinoma. Eur J Cancer 26:740–741.

    Article  PubMed  CAS  Google Scholar 

  58. Jones DH, Bleehen NM, Slater AJ, George PJM, Walker JR, Dixon AK. 1983. Human lymphoblastoid interferon in the treatment of small cell lung cancer. Br J Cancer 47: 361–366.

    Article  PubMed  CAS  Google Scholar 

  59. Jackson D, Caponera M, Muss H, Ruduick S, Spurr C, Capizzi R. 1984. Interferon α2 in advanced small cell carcinoma of the lung. Proc ASCO 3:226.

    Google Scholar 

  60. Mattson K, Holsti LR, Niiranen A, Kivisaari L, Iivanainen M, Sovijärvi A, Cantell K. 1985. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. J Biol Respir Modif 4:8–17.

    CAS  Google Scholar 

  61. Newman HFV, Bleehen NM, Galazka A, Scott E. 1987. Small cell lung carcinoma: a phase II evaluation of r-interferon-γ. Cancer 60:2938–2940.

    Article  PubMed  CAS  Google Scholar 

  62. Sklarin N, Chahinian AP, Feuer EJ, Lahman LA, Szrajer L, Holland JF. 1988. Augmentation of activity of cis-diamminedichloroplatinum (II) and mitocycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48:64–67.

    PubMed  CAS  Google Scholar 

  63. Walsh C, Speyer JL, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum RH. 1989. Phase I study of the combination of alpha-2 interferon and cisplatinum. J Biol Respir Modifiers 8(1):11–15.

    CAS  Google Scholar 

  64. Schiller JH, Storer B, Dreicer R, Rosenquist D, Frontiera M, Carbone PP. 1989. Randomized phase II–III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell lung cancer of the lung. J Natl Cancer Inst 81:1739–1743.

    Article  PubMed  CAS  Google Scholar 

  65. Rosso R et al. 1989.

    Google Scholar 

  66. Bowman A, Fergusson RJ, Allan SG, Stewart ME, Gregor A, Cornbleet MA, Greening AP, Crompton GK, Leonard RCF, Smyth JF. 1990. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 1:351–353.

    PubMed  CAS  Google Scholar 

  67. Rosell R, Carles J, Ariza A, Moreno I, Ribelles N, Solano V, Pellicer I, Barnadas A, Abad A. 1991. A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer. Cancer 67:2448–2453.

    Article  PubMed  CAS  Google Scholar 

  68. Ardizzoni A, Rosso R, Salvati F, Scagliotti G, Soresi E, Ferrara G, Pennucci C, Baldini E, Cruciani AR, Antilli A, Tonachella R, Rinaldi M, Genovese G, Crippa M, Gatti E, Fortini C. 1991. Combination chemotherapy and interferon-α2b in the treatment of advanced non-small cell lung cancer. Am J Clin Oncol 14(2):120–123.

    Article  PubMed  CAS  Google Scholar 

  69. Kataja V. 1993. Combination of cisplatin (CDDP) and interferon alfa-2a in advanced non-small cell lung cancer (NSCLC); an open non-randomized multicentre study. Proc ASCO 12:350(A1177).

    Google Scholar 

  70. Giaccone G, Donadio M, Bonardi G, Silvestro L, Viano I, Cotevino G, Vinzio M, Genazzani E, Calciati A. 1989. Phase II study of alpha-interferon plus bleomycin in advanced non-small cell lung cancer. Anticancer Res 9:405–408.

    PubMed  CAS  Google Scholar 

  71. Lind MJ, Gomm S, Simmonds AP, Ashcroft L, Kamthan A, Gurney G, Thatcher N. 1991. A phase II study of ifosfamide and a2b-interferon in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 28:142–144.

    Article  PubMed  CAS  Google Scholar 

  72. Jansen RLH, Slingerland R, Hoo Goey S, Franks CR, Bolhuis RLH, Stoter G. 1992. Interleukin-2 and interferon-α in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 12:70–73.

    Article  PubMed  CAS  Google Scholar 

  73. Cellerino R, Tummarello D, Graziano F, Santo A, Pasini F, Isidori P, Pedeli A, Ferretti B, Pieroni V. 1993. Advanced non-small cell lung cancer (ANSCLC): phase II study with rIL-2 & α-IFN in patients responsive or stable to induction chemotherapy. Proc ASCO 12:348(A1169).

    Google Scholar 

  74. Jett JR, Su JQ, Maksymiuk AW. 1992. Phase III trial of recombinant interferon gamma (r IFN-γ) in complete responders (CR) with small cell lung cancer (SCC). Proc ASCO 11:267(A956).

    Google Scholar 

  75. Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Kumpulainen E, Cantell K. 1992. Natural interferon alpha as maintenance therapy for small cell lung cancer. Eur J Cancer 28A(8/9): 1387–1391.

    Article  PubMed  CAS  Google Scholar 

  76. Kohne-Wompner CH, Koschel G, Pawel JV, Wilke H, Vallée D, Bremer K, Schroder M, Kaukel E, Eberhard W, et al. 1992. Carboplatin, etoposide, vincristine chemotherapy plus radiotherapy in limited desease small-cell lung cancer followed by maintenance with interferon alpha-2B versus observation. Proc ASCO 11:A1027.

    Google Scholar 

  77. Kelly K, Bunn PA, Musuka N, Beasley K, Crowley J, Livingston R. 1993. The role of alpha interferon (rINFa2A) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: a southwest oncology study. Proc ASCO 12: 330(A1099).

    Google Scholar 

  78. Glisson BS, Palmer JL, Shin DM, Wester M, Markowitz AB. 1993. Phase II trial of interferon alfa (IFN) + etoposide/cisplatin induction and IFN/MEGACE maintenance in extensive small cell lung cancer. Proc ASCO 12:354(A1194).

    Google Scholar 

  79. Mattson K, Maasilta P, Halme M, Niiranen A, Pyrhönen S, Riska K, Cantell K, Eklund J. 1993. Chemotherapy plus alpha-interferon in the treatment of small cell lung cancer. Am Rev Respir Dis 147(4):A748.

    Google Scholar 

  80. Nederman T, Benediktsson G. 1982. Effects of interferon on growth rate and radiation sensitivity of cultured, human glioma cells. Acta Radiol Oncol 21:231–234.

    Article  PubMed  CAS  Google Scholar 

  81. Gould M, Kakria R, Olson B, Borden E. 1984. Radiosensitization of human bronchogenic carcinoma cells by interferon beta. J Interferon Res 4(1):123–128.

    Article  PubMed  CAS  Google Scholar 

  82. Holsti LR, Mattson K, Niiranen A, Standertskiöld-Nordenstam C-G, Stenman S, Sovijärvi A, Cantell K. 1987. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 13:1161–1166.

    Article  PubMed  CAS  Google Scholar 

  83. Real FX, Known SE, Nisce LZ, Oettgen HF. 1985. Unexpected toxicity from radiation therapy in two patients with Kaposi’s sarcoma receiving interferon. J Biol Respir Modif 4:141–146.

    CAS  Google Scholar 

  84. Jermy A, Rees GJG, Rees RC. 1983. Lack of interferon induction by radiotherapy. Br J Radiol 56:274.

    Article  PubMed  CAS  Google Scholar 

  85. Maasilta P, Holsti LR, Halme M, Kivisaari L, Cantell K, Mattson K. 1992. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 23:863–868.

    Article  PubMed  CAS  Google Scholar 

  86. Torrisi J, Berg C, Bonnern E, Dritschilo A. 1986. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 13(Suppl 2):78–83.

    PubMed  CAS  Google Scholar 

  87. Torrisi J, Berg C, Harter K, Lvovsky E, Yeung K, Wooley P, Bonnern E, Dritschilo A. 1986. Phase I combined modality clinical trial of alpha-2 interferon and radiotherapy. Int J Radiat Oncol Biol Phys 12:1453–1456.

    Article  PubMed  CAS  Google Scholar 

  88. Cottier-Fox M, Torrisi J, Spitzer TR, Deeg HJ. 1990. Increased toxicity of total body irradiation in patients receiving interferon for leukaemia. Lancet 335:174.

    Article  Google Scholar 

  89. Hagberg H, Blomkvist E, Ponten U, Persson L, Muhr C, Eriksson B, Oberg K, Olssn Y, Lilja A. 1990. Does alpha-interferon in conjugation with radiotherapy increase the risk of complications in the central nervous system? Ann Oncol 1:449.

    PubMed  CAS  Google Scholar 

  90. Kinnula V, Mattson K, Cantell K. 1989. Pharmacokinetics and toxicity of inhaled human interferon alpha in patients with lung cancer. J Interferon Res 9:419–423.

    Article  PubMed  CAS  Google Scholar 

  91. Maasilta P, Halme M, Mattson K, Cantell K. 1991. Pharmacokinetics of inhaled recombinant and natural alpha interferon. Lancet 337:371.

    Article  PubMed  CAS  Google Scholar 

  92. Halme M, Maasilta P, Repo H, Ristola M, Taskinen E, Mattson K, Cantell K. 1995. Inhaled recombinant interferon gamma in humans: pharmocokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiation Oncol Biol Phys. In Press.

    Google Scholar 

  93. Halme M, Maasilta P, Mattson K, Cantell K. 1995. Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer. Respiration 61: 105–107.

    Article  Google Scholar 

  94. Esgro JJ, Whitworth P, Fidler IJ. 1990. Macrophages as effectors of tumor immunity. Immunol Allergy Clin North Am 10:705–729.

    Google Scholar 

  95. Bocci V, Carraro F, Naldini A, Borrelli E, Biagi G, Gotti G, Ciomarelli PP. 1990. Interferon levels in human pulmonary tumours are lower than plasma levels. J Biol Regul Homeostat Agents 4:153–156.

    CAS  Google Scholar 

  96. Bocci V, Pessina GP, Pacini A, Paulesu L, Muscettola M, Mogensen KE. 1984. Pulmonary catabolism of interferons: alveolar absorption of 124I-labeled human interferon alpha is accompanied by partial loss of biological activity. Antiviral Res 4:211–220.

    Article  PubMed  CAS  Google Scholar 

  97. Halme M, Maasilta P, Repo H, Leirisalo-Repo M, Taskinen E, Mattson M, Cantell K. 1995. Subcutaneously administered recombinant interferon gamma in humans: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages, blood neutrophils and monocytes. Immunother 15:283–291.

    Google Scholar 

  98. Huland E, Huland H, Heinzer H. 1992. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:344–348.

    PubMed  CAS  Google Scholar 

  99. Bocci V. 1992. Physicochemical and biological properties of interferons and their potential uses in drug delivery systems. Crit Rev Ther Drug Carrier Syst 9:91–133.

    PubMed  CAS  Google Scholar 

  100. Beck LK, Kane MA, Bunn PA Jr. 1988. Innovative and future approaches to small cell lung cancer treatment. Semin Oncol 15:300–314.

    PubMed  CAS  Google Scholar 

  101. Borden EC, Hawkins MJ. 1986. Biologic response modifiers as adjucants to other therapeutic modalities. Semin Oncol 13:144–152.

    PubMed  CAS  Google Scholar 

  102. Itri LM, Campion M, Dennin RA, et al. 1987. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant IFN-α2a by intramuscular injection. Cancer 59:668–674.

    Article  PubMed  CAS  Google Scholar 

  103. Von Wussow P, Freund M, Block B, et al. 1987. Clinical significance of anti-IFN-α antibody titers during interferon therapy. Lancet 2:635–636.

    Article  Google Scholar 

  104. Öberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E. 1989. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 81:531–535.

    Article  PubMed  Google Scholar 

  105. Feldman M, Londei M, Buchan G. 1987. Interferons and autoimmunity. In Interferon, Vol. 9, I Gresser (ed.). Academic Press: New York, pp. 73–90.

    Google Scholar 

  106. Von Wussow P, Pralle H, Hockkeppel H-K, Jakschies D, Sonnen S, Schmidt H, Müller-Rosenau D, Franke M, Haferlach T, Zwingers T, Rapp U, Deicher H. 1991. Effective natural interferon α therapy in recombinant interferon α-resistant patients with hairy cell leukaemia. Blood 78:38–43.

    Google Scholar 

  107. Smith JW, Longo DL, Urba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord WG, Lawrence JB, Steis RG. 1991. Prolonged continuous treatment of hairy cell leukemia patients with recombinant interferon-α2a. Blood 78(7): 1664–1671.

    PubMed  Google Scholar 

  108. Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Frühbeis B, Lamche H, Lindner J, Patzelt E, Schmähung C, Schneider F-J. 1992. Low incidence of antibody formation due to long-term interferon-α2c treatment of cancer patients. Clin Invest 70:136–141.

    Article  CAS  Google Scholar 

  109. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, Klockars M, Jantunen K, Gerwin BL, Harris CC, Tuomi T, Vanhala E, Mattson K, Linnainmaa K. 1990. Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 11(4):673–681.

    Article  PubMed  CAS  Google Scholar 

  110. Manning LS, Whitaker D, Murch AR, et al. 1991. Establishment and characterisation of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47:285–290.

    Article  PubMed  CAS  Google Scholar 

  111. Hand AMS, Husgafvel-Pursiainen K, Tammilehto L, Mattson K, Linnainmaa K. 1991. Malignant mesothelioma: the antiproliferative effects of cytokine combinations on three human mesothelioma cell lines. Cancer Lett 58:205–210.

    Article  PubMed  CAS  Google Scholar 

  112. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp MJ. 1991. HLA expression and malignant mesothelioma. Am J Respir Cell Mol Biol 5:213–220.

    PubMed  CAS  Google Scholar 

  113. Hand AMS, Husgafvel-Pursiainen K, Pelin K, Vallas M, Suitiala T, Ekman A, Mattson M, Mattson K, Linnainmaa K. 1992. Interferon-α and-γ in combination with chemo-therapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines. Anti-Cancer Drugs 3:687–694.

    Article  PubMed  CAS  Google Scholar 

  114. Manning LS, Bowman RV, Darby SB, Robinson BS. 1989. Lysis of human malignant mesothelioma cells by natural killer and lymphokine-activated killer cells. Am Rev Respir Dis 139:1369–1374.

    PubMed  CAS  Google Scholar 

  115. Robinson BWS, Bowman R, Christmas T, Musk AW, Manning LS. 1991. Immunotherapy for malignant mesothelioma: use of interleukin-2 and interferon alpha. In Interferons and Cytokines, HC Thomas, M Talpaz, and R Penny (eds.). Mediscript: London, 1991.

    Google Scholar 

  116. Chahinian AP, Norton L, Holland JF, et al. 1984. Experimental and clinical activity of mitocycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 44:1688–1692.

    PubMed  CAS  Google Scholar 

  117. Boutin C, Viallat JR, Astoul P. 1990. Treatment of mesothelioma with interferon gamma and interleukin-2. Rev Pneumol Clin 46(5):211–215.

    PubMed  CAS  Google Scholar 

  118. Chicheportiche C, Laurent JC, Bethaj M, Rey F, Astoul P, Ponchetet P, et al. 1992. Immuno-biological monitoring of patients with malignant pleural effusions treated with intrapleural interferon γ. Proc Am Assoc Cancer Res 33:246(A1476).

    Google Scholar 

  119. Douillard JY, Boutin C, Bignon J, Guerin JC, Van Derschueren R, Brandely M. 1992. Intrapleural recombinant human gamma interferon (rhγ IFN) in the treatment of malignant pleural mesothelioma. Proc ASCO 11:307(A1037).

    Google Scholar 

  120. Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE. 1990. Phase II evaluation of recombinant interferon-β (IFN-βser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 10:531–534.

    Article  Google Scholar 

  121. Hand AMS, Pelin K, Halme M, Mattson M, Ekman A, Linnainmaa K. Submitted. Interferons and methotrexate: in vitro sensitivity studies in 4 malignant mesothelioma cell lines.

    Google Scholar 

Download references

Authors
  1. Karin V. Mattson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne M. Hand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paula K. Maasilta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology 5074, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Heine H. Hansen

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mattson, K.V., Hand, A.M., Maasilta, P.K. (1994). Interferon and lung cancer. In: Hansen, H.H. (eds) Lung Cancer. Cancer Treatment and Research, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2630-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2630-8_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6128-2

  • Online ISBN: 978-1-4615-2630-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation